Upper limb fracture
Conditions
Interventions
Experimental group (CSA group):The cross-sectional area (CSA) of the brachial plexus is measured under the ultrasound short-axis section. Using 0.5% ropivacaine, the injection volume was calculated ba
Control group 1 (empirical group):0.5% ropivacaine is used, and the injection volume is determined by the on-call anesthesiologist based on clinical experience.
Control group 2 (regroup):Using 0.5% ropivacaine, the required dose is calculated at 2.5 mg/kg.
Pre-experimental group:Sequential BCD-UDM Design with Bias Curve, Centred Isometric Regression Method for MEV90 (Measurement Coefficient) .Initial Dose Coefficient: 0.3 mL/mm2 (0.5% Ropivacaine)Stepwi
Sponsors
North Jiangsu People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1.Age 18–80 years old, proposed for elective unilateral upper extremity surgery; 2.ASA grade I–III; 3.Planned to undergo ultrasound-guided interscalene sulcus brachial plexus block; 4.Normal preoperative respiratory function; 5.No history of neck surgery; 6.No use of drugs that affect nerve conduction or opioids within 30 days prior to surgery
Exclusion criteria
Exclusion criteria: 1.Local infection, coagulation dysfunction, neuropathy; 2.Allergy to ropivacaine or amide local anesthetics; 3.Severe hepatic and renal insufficiency; 4.Pregnancy or lactation; 5.Expected dosing required to exceed the maximum safe single safe dose of ropivacaine; 6.Inability to cooperate with ultrasound measurements or nerve block operators.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Block success rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Block quality (whether salvage block and dose are needed);PACU VAS pain score;Changes in diaphragm function; | — |
Countries
China
Contacts
Public ContactGao Ju
North Jiangsu People's Hospital
Outcome results
None listed